Promising efficacy of the sirolimus-eluting stent in patients with acute myocardial infarction

Objectives. This study investigated the safety and efficacy of sirolimus-eluting stents (SESs) on early and late outcomes in patients with acute myocardial infarction. Methods. A series of 100 consecutive patients (September 2004 to November 2005) with acute myocardial infarction undergoing primary stenting using SES(≤ 24 hr)was compared with 100 consecutive patients (September 2003 to August 2004) treated with bare metal stent (BMS). The frequency of major adverse cardiac events (MACE) and stent thrombosis, and status of ticlopidine administration were assessed at 270 days. Results. The rates of premature discontinuation of ticlopidine (SES group < 3 months: 11%, BMS group < 1 month: 11%, p = NS)and stent thrombosis (SES group: 1%, BMS group: 0%, p = NS)were similar in the two groups. At follow-up, restenosis rate and target vessel revascularization rate were lower in the SES group(4% vs 19%, p< 0.001 and 4% vs 10%, p = 0.149, respectively). Furthermore, the occurrence of MACE at 270 days was significantly less frequent in the SES group compared with the BMS.